The incidence of melanoma has been increasing worldwide. A relationship between melanoma and the immune system was established years ago. Modulating the immune system in the management of different stages of melanoma has been the focus of numerous large randomized trials worldwide. This article reviews the current status of immunotherapy for melanoma, with a focus on the recent promising results from using vaccines, cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies, and adoptive cell therapy.
|Original language||English (US)|
|Number of pages||19|
|Journal||Surgical Oncology Clinics of North America|
|State||Published - Jan 1 2011|
- T cell
ASJC Scopus subject areas